Foghorn Therapeutics (FHTX) Competitors

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Do analysts recommend AUPH or FHTX?

Aurinia Pharmaceuticals presently has a consensus target price of $11.50, suggesting a potential upside of 35.77%. Foghorn Therapeutics has a consensus target price of $12.13, suggesting a potential upside of 157.98%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Foghorn Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Foghorn Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.13

Which has preferable valuation & earnings, AUPH or FHTX?

Aurinia Pharmaceuticals has higher revenue and earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$235.13M	4.87	$5.75M	$0.28	30.25
Foghorn Therapeutics	$22.60M	11.59	-$86.62M	-$1.36	-3.46

Do institutionals & insiders hold more shares of AUPH or FHTX?

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the media favor AUPH or FHTX?

In the previous week, Aurinia Pharmaceuticals had 7 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 9 mentions for Aurinia Pharmaceuticals and 2 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.70 beat Aurinia Pharmaceuticals' score of 0.65 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Foghorn Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more risk & volatility, AUPH or FHTX?

Aurinia Pharmaceuticals has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.05, indicating that its stock price is 205% more volatile than the S&P 500.

Is AUPH or FHTX more profitable?

Aurinia Pharmaceuticals has a net margin of 16.11% compared to Foghorn Therapeutics' net margin of -342.23%. Aurinia Pharmaceuticals' return on equity of 14.27% beat Foghorn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	16.11%	14.27%	9.93%
Foghorn Therapeutics	-342.23%	N/A	-27.28%

Summary

Aurinia Pharmaceuticals beats Foghorn Therapeutics on 9 of the 17 factors compared between the two stocks.